Marstacimab is the first subcutaneous option for hemophilia B, reducing reliance on frequent IV infusions and improving patient quality of life. The phase 3 BASIS trial showed marstacimab reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback